Innate Pharma SA (OTC:IPHYF) – Equities research analysts at Leerink Swann decreased their FY2017 earnings estimates for Innate Pharma SA in a research report issued on Monday. Leerink Swann analyst M. Schmidt now anticipates that the company will post earnings of ($1.13) per share for the year, down from their prior forecast of ($0.62). Leerink Swann also issued estimates for Innate Pharma SA’s FY2018 earnings at ($1.14) EPS.

Separately, HC Wainwright reiterated a “buy” rating on shares of Innate Pharma SA in a report on Wednesday, August 30th.

COPYRIGHT VIOLATION WARNING: This story was published by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at

Shares of Innate Pharma SA (IPHYF) opened at 12.53 on Wednesday. Innate Pharma SA has a one year low of $10.72 and a one year high of $16.55. The company has a market capitalization of $676.52 million, a P/E ratio of 45.56 and a beta of 1.44. The firm has a 50-day moving average of $12.73 and a 200-day moving average of $12.59.

Receive News & Ratings for Innate Pharma SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma SA and related companies with's FREE daily email newsletter.